Drug-induced Neurological Disorders
There are now thousands of agents, synthetic or of natural origin, which are used for the investigation, control, prevention and treatment of disease in man. They possess widely different physicochemical structures and properties and it is not surprising that from time to time their administration is followed by some form of tissue reaction which was unintended by the prescriber. There seems to be no organ system which cannot be harmed by one drug or another and all levels of the nervous system may be affected.
Classification
Side-effects of drug therapy (Table 1) may arise in five different ways:
(1) Hypersensitivity reaction or drug allergy: Drug allergy is a loosely used term for the multiplicity of sensitivity reactions which include fever, skin eruptions, oedema, joint swelling, lymphadenopathy and hvmatological abnormalities. In the majority of cases these reactions cannot be proved to involve an antigen-antibody mechanism as in the case of apronal-induced thrombocytopenia. It is possible, however, that in some examples of drug-induced polyneuritis and encephalitis there is an allergic arteritis.
(2) Exaggerated therapeutic effect: Examples of this type of reaction are provided by the alarming and sometimes fatal misuse of the anticoagulants and the antihypertensive drugs.
(3) Subsidiary pharmacological effect: Side-effects may represent no more than another pharmacological property of the drug prescribed. There are many examples of these, such as the soporific effect of the antihistamines, the disappearance of the normal intestinal flora during antibiotic treatment and the hormonal imbalance during steroid treatment.
(4) Genetic circumstances: In other instances the side-effect is genetically determined. Here we are in the field of 'pharmacogenetics' and we already have the examples of primaquine-induced hemolytic aneemia and suxamethonium-induced apnrea.
In both cases we are dealing with the consequences of inherited enzyme deficiency: glucose-6-phosphate dehydrogenase in the former and pseudocholinesterase in the latter. There will be others, and chance clinical observation may provide the first clue as in the case of the Japanese surgeon who noticed that occasionally hydrogen peroxide did not foam in the mouth (Takahara 1952) . This proved to be due to the absence of the enzyme catalase in human saliva and blood.
In diabetes mellitus and porphyria we are dealing with inherited abnormalities the symptoms of which may appear spontaneously or through the intervention of some agent. In the case of diabetes mellitus it may be steroid treatment; in porphyria, barbiturates or sulphonamides. More interesting still is the possibility that the agent precipitating the crises in these inherited abnormalities may not be a drug but a normal article of diet. In favism, in which again there is a deficiency of glucose-6-phosphate dehydrogenase, broad beans are the agent responsible for the onset of the acute haemolytic anemia. Some similar mechanism may be at work in lathyrism. Nearer home, the possibility of interactions between one drug and another, and between one drug and some article of food, may conceivably involve genetic factors. The remarkable examples of possible interaction between cheese and tranylcypromine are most interesting. One such case I saw, through the courtesy of Dr Brian Thomas of Penarth, developed an acute hypertensive crisis within forty minutes of taking these substances together. The picture was similar to that in acute subarachnoid haemorrhage except that the onset was not so abrupt; lumbar puncture revealed a clear fluid. This patient had been taking the drug for two weeks and had eaten cheese during that time without discomfort.
The thalidomide tragedy made teratogenicity testing of drugs essential; drug interactions and food-drug interactions could make things even more difficult for manufacturer and prescriber. (5) True toxicity: Here we are often dealing with the results of prolonged treatment. Two not uncommon examples I should like to mention are of the over-treated epileptic child and the elderly person with parkinsonism. The child may be taking three different anti-convulsants and not only do his fits continue but he is noticeably retarded and often clumsy. The old person is trying to take one or two drugs which have little if any therapeutic effect and reduce him to a state in which he feels muddled and depressed. There has often been little attempt to determine the optimum dosage in such cases and a dossier of suggestions is to be found where instead there should be the personal observations of the patient's practitioner.
At other times the cumulative toxic effect of a drug is brought about because of impaired renal function. Elderly patients or those with renal disease are specially susceptible to drugs such as streptomycin, nitrofurantoin and the ganglionoplegic anti-hypertensive drugs. In an old woman with polyneuritis a nephrectomy scar was the clue to the cause of her illness, namely three courses of nitrofurantoin.
Convulsants
There are many drugs which, if given in sufficient quantity, will cause convulsions and coma, but we are here mainly interested in those drugs in common use which may occasionally cause convulsion. The side-effects of phenothiazines are well documented and I shall not deal with them. What with liver damage, blood disorders, skin reactions, disturbances of the extrapyramidal system, syncope and types of agitation, these drugs are unique. The neurologist at least hopes that the manner in which they produce various striking disorders of the extrapyramidal system will provide the neurophysiologist, in due course, with information concerning the normal function of this ill-understood part of the nervous system. Convulsions are fortunately rare. Chlorpromazine, promazine and thiopropazate may aggravate an epileptic tendency or even induce an epileptic fit for the first time. Reserpine is another drug widely used as a tranquillizer or antihypertensive agent which may cause epilepsy. It is probably one of the most potent depressant drugs in common use.
Isoniazid, which I shall mention in connexion with peripheral neuropathy, is another occasional convulsant. Psychosis due to isoniazid is also well recognized; it was reported in 4 of 173 patients treated in the first Medical Research Council's trial in 1952. Chlorambucil, a nitrogen mustard derivative, has also recently been shown to possess marked epileptogenic properties (Pradhan & Marsan 1963) . Electroencephalographic investigation in experimental animals revealed the quite prominent development of bilateral synchronous 3-4/sec spike and wave complexes. The excitatory effects of the drug in the human being have been described by French and colleagues (1952) and Wolfson & Olney (1957) .
But to the practising clinician the most important drug with convulsant properties is probably cycloserine. It is curious that three widely used antituberculous agents, isoniazid, streptomycin and cycloserine, should have such striking neurotoxic effects. Cycloserine has been reported to be somewhat less effective against tuberculosis than streptomycin or isoniazid. It is active against tubercle bacilli which are resistant to the effects of streptomycin or isoniazid but its neurotoxic effects considerably restrict its therapeutic value. Some authorities believe that cycloserine should only be used in hospital in-patients where close observation can be maintained. The drug has the chemical structure of D-4-amino-3-isoxazolidine and it diffuses into the cerebrospinal fluid. The United States Public Health Service conducted a double-blind control study of the toxic effects of this drug and recorded convulsions, mental disorders, somnolence, dizziness, fever and chills. Of patients receiving 0 5 g cycloserine twice a day 44% experienced toxic reactions (Murray 1956). Toxic effects most commonly arise within the first sixteen days of treatment and electroencephalography proved of no assistance in the evaluation or anticipation of toxicity (Katz 1956 ). EEG abnormalities were seen in patients before treatment and during treatment in the groups with and without toxic manifestations. Murray also recorded that EEG changes were found with equal frequency among toxic and non-toxic patients receiving cycloserine and a placebo. My attention was drawn to this subject a few years ago when I saw a middle-aged woman who had recently suffered several epileptic fits, and who had been taking cycloserine for two years without apparent untoward effect. It is this type of case which is most important to the practising clinician, namely when the complication is occasional and the drug has been taken for a considerable time without obvious signs of toxicity. As in the case of the mephenesin-induced depigmentation of hair, the pills in the handbag may reveal the source of the trouble where intensive investigation proves negative (Spillane 1963) .
Toxic Disorders ofthe Cranial Nerves I have never met anosmia resulting from any oral medication, but, as is well known, the abuse of nasal drops occasionally causes this complication. Miosis resulting from eserine and pilocarpine or morphine do not need discussion here, but perhaps it is well to be reminded of the importance of the barbiturates in causing nystagmus. This fact is well known, but still leads to diagnostic delays and errors. Fleeting motor and sensory symptoms in a neurotic young woman taking amylobarbitone sodium 3 gr at night may, because of persistent nystagmus, puzzle a hospital clinician in his morning outpatient clinic; such nystagmus usually subsides by midday. In my experience alcohol is a less frequent source of trouble but, paradoxically, it may reduce congenital nystagmus temporarily. (A patient of mine with gross congenital nystagmus lost many a dancing partner after a turn around the ballroom, only to discover, when he was older, that two pints of beer before the dance assured him temporary freedom from this embarrassing stigma. Still later, after marriage, he soon discovered that to his wife absence of nystagmus meant that he had taken at least two pints of beer on the way home!) Stilbamidine, formerly used for the treatment of kala-azar, still deserves mention because of the unique manner in which it produces selective trigeminal sensory impairment. It achieved a short-lived popularity in the treatment of trigeminal neuralgia. The extrapyramidal effects of phenothiazines may sometimes reveal themselves by the onset of dyskinetic movements confined to the muscles of the eyeballs, face, mouth and tongue. Any bizarre symptoms of acute onset accompanied by involuntary movements in this region should raise the question of phenothiazine toxicity. The syndromes can occur on first taking the drug, and appear within a few days, in susceptible individuals. A torticollis of twenty-four hours duration in one young boy I saw proved to be due to perphenazine which he had pilfered from his mother's bedroom.
Optic atrophy from arsenicals and amblyopia from quinine are rare but widely recognized complications of treatment. Retinal damage simula-ting retinitis pigmentosa has been described following certain phenothiazine derivatives, including thioridazine (May et al. 1960) . Chloramphenicol, the only effective drug in the treatment of typhoid fever, is of course highly toxic and should not be prescribed unless absolutely necessary. Wilson has drawn attention to several cases of serious visual disturbance arising during chloramphenicol treatment (1962) .
(1) Chloroquine retinopathy: This drug is a quinine derivative widely prescribed for rheumatoid arthritis and lupus erythematosus. It can produce both corneal and retinal changes (Hobbs et al. 1959 , Hobbs et al. 1961 . A survey revealed that 30% of patients treated with antimalarial drugs developed corneal changes. In most cases these changes were symptomless and regressed with the withdrawal of treatment. A characteristic symptom is the appearance of haloes around naked lights. On the other hand, the retinal changes (arterial attenuation, oedema and pigmentary disturbances) are largely irreversible. These more serious retinal changes are not always accompanied by corneal deposits. The typical field defect is a ring scotoma which later breaks through to the periphery. Changes similar to those found in retinitis pigmentosa may be seen and symptoms are usually those of the field defect together with night blindness. Routine testing of visual acuity during chloroquine treatment is not sufficient to exclude the development of toxic retinal changes because foveal vision is affected comparatively late. In one patient bilateral central ring scotomata were present before macular changes could be identified (Spillane 1962 ).
(2) Isoniazid optic neuropathy: Optic atrophy with or without blindness has been observed in patients given isoniazid for the treatment of pulmonary tuberculosis (Sutton & Beattie 1955 , Dixon et al. 1956 ). Stopping isoniazid reversed the process according to two reports (Keeping & Searle 1955 , Kass et al. 1957 . In one fatal case Dixon and his colleagues found demyelination of the optic tracts as well as softening of the grey matter of the spinal cord. Lorber (1956) has commented on the high incidence of visual complications associated with the intrathecal method of administration of this drug in tuberculous meningitis. In most cases it is not necessary to give the drug intrathecally.
(3) Steroid therapy andpapillwdema: Papilloedema due to benign intracranial hypertension during steroid therapy has been reported by several clinicians (Dees & McKay 1959 , Valentine 1959 , Laurance et al. 1960 , Greer 1963 ). In the first report an account was given of three young boys with longstanding severe asthma on protracted steroid therapy developing headache, diplopia, vomiting, ataxia and papilloedema. The cerebrospinal fluid was under greatly increased pressure but was otherwise normal and the ventricular systems were small and normally situated. All three patients had acquired the appearance of Cushing's disease. Valentine's patient was a child aged 4 with the nephrotic syndrome. She had taken prednisolone and later triamcinolone. The CSF pressure was greatly increased, but the fluid was normal and bilateral carotid arteriography and air encephalography were normal. When the triamcinolone was withdrawn and replaced with prednisolone the papilloedema started to subside in two weeks and after two months the discs were normal. The two cases described by Laurance and his colleagues were also children suffering from asthma: Both had been on prednisolone and later transferred to triamcinolone. Investigations confirmed the diagnosis of benign intracranial hypertension and the optic discs returned to normal when the triamcinolone was withdrawn. Greer reported 5 further cases, all children. Again triamcinolone was the drug being administered to all 5 patients before the appearance of symptoms. Greer, however, thought that a specific toxic effect of this drug was not an acceptable explanation since 4 of the 9 patients previously reported had never received triamcinolone. Papillcedema has been observed in Addison's disease (Jefferson 1956 , Walsh 1952 ) so that adrenal insufficiency must be considered in seeking an explanation for this syndrome. Adrenal insufficiency has been shown to cause an alteration in cerebral volume and ion transport in experimental animals. This may prove the basis for the cerebral cedema and the increased intracranial pressure noted clinically during prolonged steroid therapy.
(4) Streptomycin ototoxicity: The vestibular and cochlear disturbances arising from streptomycin administration are well known and were soon recognized. The onset of vertigo occurs usually during the first month of treatment and signs of vestibular damage are present in about half the patients receiving 1 g daily. It seems that a prolonged course of streptomycin with a small daily dose is just as damaging as a short course with high dosage. When used intrathecally, as was common before the introduction of isoniazid, the incidence of vestibular damage was higher. In young subjects the vertigo clears almost completely within a few weeks when medication is stopped. In older subjects recovery may be slower and incomplete. It is rare to find that streptomycin causes any delayed vestibular damage, presenting months after cessation of therapy. On the other hand loss of hearing may be insidious and the possibility of deafness must be reckoned with, not only throughout the period of treatment with streptomycin, but also for some months afterwards. In elderly people with impaired renal function the incidence of ototoxic effects of streptomycin is increased. In such people the drug should be used with great caution. I have seen permanent ataxia with a moderate degree of deafness in an elderly person treated with streptomycin during a bout of cholecystitis. He received 1 g of streptomycin intramuscularly each day for only twelve days. He was subsequently shown to have considerable impairment of renal function. The streptomycin blood level is of decisive importance and this depends on the dose per kg body weight. Irreparable damage seldom occurs with less than 24 mg/kg body weight (Meyler & Peck 1962) .
Peripheral Neuropathy
The heavy metals such as arsenic, lead and mercury no longer enter the field here in the form of Fowler's solution, lead-containing pastes and lotions, and teething powders. I understand that infantile acrodynia ('pink disease') as a cause of polyneuropathy was almost certainly related to the mercury in teething powders and in calomel anthelminthics. Thalidomide neuropathy is no longer with us although some of my patients have still not fully recovered. This toxic neuropathy was mainly of a sensory kind and paralysis was rare, but one of my patients presented with coarse and obvious fasciculation of the calf muscles. A long time elapsed between the introduction of thalidomide and the recognition that it could produce neuropathy. Before any publication on the subject one of my patients, a retired pharmacist, actually wrote to the manufacturers of Distaval but as she had suffered from pulmonary tuberculosis and received a long course of streptomycin the agent responsible for her ataxia and paresthesix was not suspected.
Gold salts, introduced for the treatment of rheumatoid arthritis in 1932, are still widely used. Approximately 25 % of the patients on gold therapy develop a rash or some other form of gold intoxication such as stomatitis or gastroenteritis. I have never seen a case of peripheral neuropathy arising from gold therapy and believe that in this country it must be rare. It is often very difficult to decide whether a neuropathy during the course of a chronic illness has been brought about by drug therapy. I recollect two patients with ankylosing spondylitis treated by irradiation who subsequently developed arthritis and peripheral neuropathy. One of them (Fig 1) also developed pulmonary tuberculosis and received cycloserine, isoniazid and sodium aminosalicylate. He suffered occasional fits, presumably due to cycloserine, but as he had also had several courses of phenylbutazone for his arthritis, it was not possible to blame the isoniazid for his neuropathy. Phenylbutazone neuropathy Fig 1 A patient with ankylosing spondylitis, arthritis and pulmonary tuberculosis. Epilepsy resulted from cycloserine, and neuropathy followed isoniazid and phenylbutazone appears to regress fairly rapidly on withdrawal of the drug (Kelly 1954 , Arden 1954 ; the neuropathy in my patient was permanent. In the second patient, on the other hand, the neuropathy and arthritis occurred within the same year, while he was taking no drugs, and at a time when his spondylitis was not very troublesome.
(1) Isoniazid neuropathy: Isoniazid has been used for the treatment of tuberculosis for nearly ten years and in ordinary dosage there is a remarkable lack of toxic effects. The nervous system is most commonly affected with the production of peripheral neuropathy, convulsions, optic atrophy and psychoses. Peripheral neuropathy is the commonest complication and was noted soon after the introduction of the drug. The incidence of toxicity is largely a reflection of the size of the dosage and the duration of treatment. Symptoms are infrequent during the administration of isoniazid 5-10 mg/kg body weight daily. The incidence of neuritis was reported to be particularly high in patients on second or subsequent courses of treatment (Biehl & Nimitz 1954) . Experimental studies showed that the neuritis resembled that induced by the vitamin B8 (pyridoxine) antagonist, desoxypyridoxine (Biehl & Vilter 1954) . When these authors studied the pyridoxine metabolism of tuberculous patients receiving isoniazid they found a considerable increase in the urinary excretion of pyridoxine metabolites. This increase was in proportion to the dose of isoniazid. The abnormal excretion disappeared on discontinuing the drug. Isoniazid neuropathy appears to be a form of conditioned pyridoxine deficiency. Pyridoxine is required for the metabolism of tryptophan and in its absence xanthurenic acid appears in the urine, as it did in patients on isoniazid. The administration of the vitamin to these patients stops the excretion of xanthurenic acid. Biehl & Vilter and others subsequently found that pyridoxine is effective in the prevention and treatment of isoniazid neuropathy.
Pyridoxine is not the only member of the vitamin B group which may become deficient during isoniazid therapy and these substances should be provided during anti-tuberculous treatment. Recent evidence suggests that differences in the rates of metabolism of isoniazid are genetically controlled (Evans 1963) . The differences appear to be due to rates of acetylation of the drug. The slow inactivators seem to be more prone to polyneuritis as a complication of prolonged treatment (Hughes et al. 1955 ).
(2) Nitrofurantoin neuropathy: Nitrofurantoin has been widely employed for its antibacterial activity especially in infections of the urinary tract. The nitrofurantoins have also been used for the treatment of metastatic testicular carcinoma. A severe polyneuropathy has usually developed in those cases when a beneficial effect has been obtained on the carcinoma (Collings 1960) . In 1954 Hasen & Moore referred to 2 out of 100 patients being treated with nitrofurantoin who complained of disturbed sensation in an extremity after one week of therapy. The symptoms subsided when the drug was discontinued, but recurred in one of them when it was restarted. Between 1955 and 1960 there were several further hints that serious neuropathy might be an occasional complication. Two recent reports from this country (Loughridge 1962 , Ellis 1962 ) stress the importance of impaired renal function in producing this complication. Elderly people with elevated blood urea usually develop plasma levels of nitrofurantoin which are much higher than those patients with a normal blood urea level. Ellis reported that the drug was not withdrawn after the development of neuropathy in 3 of his 6 cases; their condition deteriorated rapidly and they died. In 3 later cases withdrawal of the drug was followed by slow partial recovery. By 1962 there appear to have been not more than 20 cases of nitrofurantoin neuropathy reported in the literature (Martin et al. 1962) . But mild degrees of nitrofurantoin neuropathy in elderly people could easily go unrecognized; I have seen several.
Autopsy in one of the 4 cases described by
Collings revealed mild degeneration of peripheral nerves with retrograde degeneration of the anterior horn cells of the spinal cord. Histological examination of affected muscles revealed the characteristic changes of neurogenic muscular atrophy. The mechanism by which nitrofurantoins produce peripheral neuropathy is not known. As it has developed on patients simultaneously receiving the B vitamins, conditioned deficiency of these vitamins is an unlikely explanation. There was no disturbance of pyruvate metabolism in one of my cases and Ellis found pyruvate tolerance tests were normal. It appears that a daily dose of 400 mg should be given for not more than two weeks, but a small daily dose can probably be given safely for a longer period.
Myopathy
The commonest danger during steroid therapy is peptic ulcer and himatemesis. Other well-known effects are diabetes, hypercortisonism, psychosis and myopathy. Many clinicians had noted wasting of thigh muscles in patients with rheumatoid arthritis on cortisone, but it was not until 1957, with the introduction of triamcinolone, that serious muscle weakness was reported as a complication. Freyberg et al. (1958) reporting the first clinical trial of triamcinolone referred briefly to side-effects not often noted with other steroids, namely postprandial flushing, headache, loss of weight and muscular weakness. Eleven of their 89 patients complained of muscular weakness. Triamcinolone causes less water and salt retention than its forerunners and dermatologists have found it the most useful of the steroids in the treatment of various skin diseases. Dubois (1958) , Kendall & Hart (1959) and others have all described cases in which triamcinolone therapy has been followed, sooner or later, by extensive weakness and wasting of muscles of the shoulder and pelvic girdles and the extensors of the thighs. Electromyography revealed evidence of severe muscle fibre lesion while biopsy revealed widespread necrosis.
Subsequently Golding & Begg (1960) reported a similar case of myopathy with electromyographic evidence in a patient receiving dexamethasone, a very potent synthetic corticosteroid. In several of the cases reported the myopathy has been reversed when the offending steroid has been withdrawn and prednisone substituted. Muscular wasting can undoubtedly occur during treatment with any of the anti-inflammatory steroids but most of the severe cases have been reported with fludrocortisone, triamcinolone and dexamethasone. The myopathy seems to be associated with those adrenal steroids which contain a fluorine atom in the 9-a position of the nucleus, although it must be remembered that the newer antiinflammatory steroids are much more powerful than cortisone and prednisone.
Dr Ian Skottowe (The Warneford Hospital, Oxford)
Neurological Complications of Psychiatric Treatment Modern Drugs and Methods ofTreatment Neurological complications of psychiatric treatment may arise from the use of modem tranquillizing and anti-depressant drugs and occasionally from common physical methods of treatment, such as electro-convulsion therapy (ECT), modified insulin and cerebral surgery. More than one of these drugs and methods may be applied successively or simultaneously to the same patient. The tranquillizers most commonly used are phenothiazine derivatives such as chlorpromazine, trifluoperazine and perphenazine. In less common use are the rauwolfia derivative reserpine and the compound known as haloperidol. Tranquillizing drugs in full doses are used chiefly in the treatment of schizophrenia, less frequently in mania; and in moderate doses they are used, sometimes in combination with anti-depressants, to control restlessness and agitation, especially in elderly patients. A special use is their combination with modified insulin, in the treatment of anorexia nervosa and delirium tremens. Mention may be made of lithium carbonate which, although not a
